Skip Nav Destination
Drug Discovery
Emerging Drugs and Targets for Parkinson’s DiseaseCheck Access
Edited by
Ana Martinez;
Ana Martinez
Centro de Investigaciones Biologicas-CSIC, Spain
Search for other works by this author on:
Carmen Gil
Carmen Gil
Centro de Investigaciones Biológicas (CSIC), Spain
Search for other works by this author on:
Hardback ISBN:
978-1-84973-617-6
PDF ISBN:
978-1-84973-735-7
Special Collection:
2013 ebook collection
,
2011-2015 industrial and pharmaceutical chemistry subject collection
Series:
Drug Discovery Series
No. of Pages:
402
Published online:
18 Jul 2013
Published in print:
29 Jul 2013
Book Chapter
CHAPTER 3: Dopaminergic Treatments for Parkinson’s Disease: Light and Shadows Check Access
By
Nicola Simola
Nicola Simola
Department of Biomedical Sciences
Section of Neuropsychopharmacology, University of Cagliari
Cagliari, Italy
[email protected]
Search for other works by this author on:
-
Published:18 Jul 2013
-
Special Collection: 2013 ebook collection , 2011-2015 industrial and pharmaceutical chemistry subject collectionSeries: Drug Discovery Series
Page range:
61 - 82
Citation
N. Simola, in Emerging Drugs and Targets for Parkinson’s Disease, ed. A. Martinez and C. Gil, The Royal Society of Chemistry, 2013, pp. 61-82.
Download citation file:
Dopamine‐replacement therapy still stands as the most effective pharmacological strategy for the management of motor impairment associated with Parkinson’s disease. The present chapter aims to provide an overview of the pharmacology of dopamine‐replacement therapy in both preclinical experimental models of Parkinson’s disease and patients, and to present its light and shadows. The effect of dopamine‐replacement therapy on motor impairment, motor complications, non‐motor symptoms, and disease progression will be discussed, with a focus on future therapeutic directions.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Digital access
$64.60
